LGVN Q4 2022 Earnings — Longeveron Inc. Revenue & Financial Results | Market Cap Arena

LGVNLongeveron Inc.

$20M

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$121,000-42.1% YoY

Gross Profit

-$55,000-45.5% margin

Operating Income

-$5M-4331.4% margin

Net Income

-$4M-3683.5% margin

EPS (Diluted)

$-2.10

QoQ Revenue Growth

-54.3%

Cash Flow

Operating Cash Flow

-$2M

Free Cash Flow

-$2M

Stock-Based Comp.

$306,000

Balance Sheet

Total Assets

$27M

Total Liabilities

$7M

Stockholders' Equity

$21M

Cash & Equivalents

$11M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$121,000	$209,000	-42.1%
Gross Profit	-$55,000	$69,000	-179.7%
Operating Income	-$5M	-$4M	-30.0%
Net Income	-$4M	-$4M	-9.5%